Opportunity
Simpler Grants.gov #RFA-HL-26-018
NHLBI Catalyze Program Grant for Early-Stage Product Definition in Small Molecules, Biologics, and Combination Products
Buyer
National Institutes of Health
Posted
November 22, 2024
Respond By
December 23, 2027
Identifier
RFA-HL-26-018
NAICS
541715
The National Institutes of Health (NIH), through the National Heart, Lung, and Blood Institute (NHLBI), is seeking applications for the Catalyze Product Definition initiative to advance early-stage product development for heart, lung, blood, and sleep (HLBS) diseases. - Government Buyer: - National Institutes of Health (NIH) - National Heart, Lung, and Blood Institute (NHLBI) - Products/Services Requested: - Early-stage translational support services for identifying and characterizing small molecules, biologics, and combination products - Focus on product definition and preclinical development activities - No clinical trials permitted under this initiative - Unique/Notable Requirements: - Supports transition from basic science to viable diagnostic and therapeutic products - Aims to develop translational researchers with product development and entrepreneurship skills - Open to a broad range of applicants: government, businesses, nonprofits, and educational institutions - No specific OEMs, vendors, products, or part numbers are identified in this opportunity - Place of Performance: - National Institutes of Health (federal office)
Description
The NHLBI Catalyze Program aims to support the transition of basic science discoveries into viable diagnostic and therapeutic candidates cleared for human testing, focusing on translational researchers skilled in product development and entrepreneurship. This specific initiative provides early-stage translational support to identify and characterize potential therapeutic candidates and combination products for HLBS diseases and disorders. It is part of a suite of innovation grants designed to advance projects to meet entry criteria for the NHLBI Catalyze Preclinical Program. The program excludes clinical trials and supports a range of eligible applicants including government entities, businesses, nonprofits, and educational institutions.